BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 21, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Status

Urocidin: Phase III started

Endo began the open-label, international Phase III EMBARC-RF trial in 450 patients refractory to Bacille Calmette-Guerin (BCG) therapy to compare Urocidin vs. mitomycin C for 12 months....

Read the full 112 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >